HCK Knockout HAP1 Cell Line

The choice depends on whether you are studying HCK (hematopoietic cell kinase)'s role as a Src-family kinase in myeloid cell signaling or its functions in cancer and CML therapy resistance. The Knockout line is the standard tool for asking whether HCK is required for these processes — HCK is a Src-family tyrosine kinase principally expressed in myeloid cells (macrophages, neutrophils, dendritic cells) and B cells, with established roles in phagocytosis, integrin signaling, and BCR-ABL-driven CML. Overexpression is useful for studying HCK gain-of-function in cancer contexts. Important consideration: Src-family kinases (SRC, LYN, FYN, YES, FGR, HCK, LCK, BLK) share substantial substrate scope — single HCK knockout in HAP1 may show modest phenotypes if other Src-family members compensate. This product complements the parallel LYN Knockout in HAP1 (also available) for Src-family functional dissection in myeloid context. Rescue with wild-type, kinase-dead, or Y505F (autoinhibitory phospho-site mutant, constitutively active) HCK is the standard specificity control. The knockout is valuable for studying CML imatinib resistance (HCK overexpression has been implicated) and BCR-ABL-driven leukemia mechanisms.

Primary applications: • Src-family kinase activity: phospho-HCK (Y411 activation, Y523 autoinhibition) and substrate phosphorylation analysis given HCK's autoregulatory phosphorylation. • CML imatinib resistance: in heterologous CML-relevant contexts, characterization of HCK's role in BCR-ABL signaling and imatinib resistance. • Myeloid signaling studies: in heterologous myeloid contexts, FcγR-induced phospho-Syk and downstream signaling. • Src-family inhibitor specificity: critical genetic control for dasatinib (broad-spectrum SFK inhibitor), iadademstat (HCK component), and other Src-family inhibitors. EDITGENE recommends this model for in vitro HCK biochemistry; physiological myeloid HCK research requires myeloid cell models.

Yes. HCK rescue experiments require attention to Src-family architecture and lipid modifications: • Construct design: use a codon-modified HCK sequence with a small C-terminal tag (FLAG, HA). HCK has N-terminal myristoylation/palmitoylation, SH3, SH2, kinase domain, and C-terminal Y523 regulatory tail — preserve N-terminus for proper membrane targeting. • Kinase-dead rescue: K269A mutation in the ATP-binding lysine abolishes catalytic activity. • Constitutively active rescue: Y523F mutation removes the autoinhibitory C-terminal phosphorylation site, generating constitutively active HCK. • Lipid-modification-deficient rescue: G2A mutation abolishes myristoylation and membrane association. • Functional readout: rescue should restore Src-family kinase substrate phosphorylation patterns. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.